amending Decree No 532 / 2005 Coll., on the reimbursement of medicines and foodstuffs for special medical purposes
The Ministry of Health provides pursuant to § 15 paragraph 10 of Act No. 48 / 1997 Coll., on Public Health Insurance and on the amendment and addition of certain related laws, as amended by Act No. 438 / 2004 Coll.:
Decree No 532 / 2005 Coll., on the reimbursement of medicinal products and foodstuffs for special medical purposes, is amended as follows:
Annex No 1 to Decree No 532 / 2005 Coll., on the reimbursement of medicinal products and foodstuffs for special medical purposes reads:
"Annex No 1 to Decree No 532 / 2005 Coll.
Medicinal products, including individually prepared medicinal products, radiopharmaceuticals and transfusion products, and food for special medical purposes fully covered by health insurance, the amount of payments of active substances and the amount of food payments for special medical purposes
| Číslo řádku vyhlášky | Označení ATC a V06XX | Název léčivé látky | Cesta podání | Množství | Název jedn. | Úhrada v Kč | Omezení |
| |
| 1 | Stomatologika |
| |
| 1.1 | A01AA01 | fluorid sodný | p.o. | 1.10 | MG | 0,86 | |
| 46265 | ZYMAFLUOR 1/4 MG | portblnob200x0.25mg | FAJ | I |
| 1.2 | A01AB10 | natamycin | lok. | 20.00 | MG | 7,31 | |
|
| 1.3 | A01AB03 | chlorhexidin | lok. | 1 000.00 | ML | 174,64 | H |
|
| 1.4 | A01AC01 | triamcinolon | lok. | 1.00 | GM | 13,38 | L/DER,STO, ORL |
|
| 1.5 | A01AC02 | dexametason | lok. | 1.00 | GM | 11,41 | L/DER,STO, ORL |
|
| 2 | adsobční anatacida a protivředová léčiva ze skupiny H2-blokátorů, perorální podání |
|
| 2.1 | A02AD | kombinace hliníku, vápníku a hořčíku (pevné lékové formy) | p.o. | 10.00 | DF | 3,03 | |
|
| 2.2 | A02AD | kombinace hliníku, vápníku a hořčíku (tekuté lékové formy) | p.o. | 50.00 | ML | 3,03 | |
|
| 2.3 | A02AD01 | kombinace hliníku, vápníku a hořčíku (obvyklé kombinace solí – pevné lékové formy) | p.o. | 10.00 | DF | 3,03 | |
|
| 2.4 | A02AD01 | kombinace hliníku, vápníku a hořčíku (obvyklé kombinace solí – tekuté lékové formy) | p.o. | 50.00 | ML | 3,03 | |
|
| 2.5 | A02AD04 | hydrotalcit (pevné lékové formy) | p.o. | 10.00 | DF | 3,03 | |
|
| 2.6 | A02AD04 | hydrotalcit (tekuté lékové formy) | p.o. | 50.00 | ML | 3,03 | |
|
| 2.7 | A02BA01 | cimetidin | p.o. | 0.80 | GM | 3,03 | |
|
| 2.8 | A02BA02 | ranitidin nad 75 mg v 1tbl | p.o. | 0.30 | GM | 3,03 | |
| 12346 | HISTAC 150 | tbl obd 20x150mg | RXY | IND |
| 14664 | HISTAC 150 | por tbl flm20x150mg | IRI | IRL |
| 2.9 | A02BA03 | famotidin 20 mg a výše v 1 tabletě | p.o. | 40.00 | MG | 3,03 | |
|
| 2.10 | A02BA04 | nizatidin | p.o. | 0.30 | GM | 3,03 | |
|
| 2.11 | A02BA06 | roxatidin | p.o. | 0.15 | GM | 3,03 | |
|
| 2.12 | A02BA07 | ranitidin bismut citrát | p.o. | 0.80 | GM | 27,85 | |
|
| 3 | protivředová léčiva ze skupiny inhibitorů protonové pumpy a ostatní protivředová léčiva |
|
| 3.1 | A02BA01 | cimetidin | parent. | 0.80 | GM | 31,33 | H |
|
| 3.2 | A02BA02 | ranitidin | parent. | 0.30 | GM | 66,88 | H |
|
| 3.3 | A02BA03 | famotidin | parent. | 40.00 | MG | 66,88 | H |
|
| 3.4 | A02BB01 | misoprostol | p.o. | 0.80 | MG | 46,28 | Z |
|
| 3.5 | A02BC01 | omeprazol | parent. | 20.00 | MG | 166,14 | H |
|
| 3.6 | A02BC01 | omeprazol (do 10 mg v jedné dávce včetně) | p.o. | 20.00 | MG | 13,63 | |
|
| 3.7 | A02BC01 | omeprazol (nad 10 mg v jedné dávce) | p.o. | 20.00 | MG | 8,16 | |
| 60160 | ULTOP | cps 14x20mg | KRK | SLO |
| 3.8 | A02BC02 | pantoprazol | p.o. | 40.00 | MG | 8,16 | |
| |
| 3.9 | A02BC02 | pantoprazol | parent. | 40.00 | MG | 166,14 | H |
| |
| 3.10 | A02BC03 | lansoprazol | p.o. | 30.00 | MG | 8,16 | |
| |
| 3.11 | A02BC05 | esomeprazol (do 20mg v jedné dávce včetně) | p.o. | 30.00 | MG | 17,59 | L/GIT,INT,GER |
| |
| 3.12 | A02BC05 | esomeprazol (nad 20mg v jedné dávce) | p.o. | 30.00 | MG | 9,77 | L/GIT,INT,GER |
| |
| 3.13 | A02BX | ostatní léčiva peptického vředu (bismut subsalicylat) | p.o. | 3.00 | DF | 21,78 | |
| |
| 3.14 | A02BX02 | sukralfát | p.o. | 4.00 | GM | 8,16 | |
| |
| 3.15 | A02BX03 | pirenzepin | p.o. | 0.10 | GM | 8,36 | |
| |
| 3.16 | A02BX03 | pirenzepin | parent. | 20.00 | MG | 103,18 | H |
| |
| 3.17 | A02BX05 | zásaditý citronan bismutitý | p.o. | 0.48 | GM | 22,55 | |
| |
| 4 | spasmolytika, perorální podání |
| |
| 4.1 | A03AA04 | mebeverin | p.o. | 0.30 | GM | 4,83 | |
| |
| 4.2 | A03AA05 | trimebutin | p.o. | 0.30 | GM | 4,83 | |
| |
| 4.3 | A03AB03 | oxyfenon | p.o. | 25.00 | MG | 2,25 | |
|
| 4.4 | A03AB06 | otilonium bromid | p.o. | 0.12 | GM | 12,14 | |
| |
| 4.5 | A03AB11 | poldin | p.o. | 12.00 | MG | 2,25 | |
| |
| 4.6 | A03AD01 | papaverin | p.o. | 0.10 | GM | 0,66 | |
| |
| 4.7 | A03AD02 | drotaverin | p.o. | 0.10 | GM | 4,77 | |
| 17933 | NO-SPA FORTE | tbl 10x80mg | CPW | H |
| 4.8 | A03BA01 | atropin | p.o. | 1.50 | MG | 0,48 | |
| |
| 4.9 | A03BB01 | butylskopolamin | p.o. | 60.00 | MG | 13,89 | |
| |
| 5 | spasmolytika, ostatní cesty aplikace |
| |
| 5.1 | A03AD01 | papaverin | parent. | 0.10 | GM | 17,53 | |
| |
| 5.2 | A03AD02 | drotaverin | parent. | 0.10 | GM | 24,97 | |
| 02552 | NO-SPA | inj 5x2ml/40mg | CHN | H |
| 5.3 | A03BA01 | atropin (1 mg a více v 1 ampuli) | parent. | 1.50 | MG | 7,93 | |
|
| 5.4 | A03BA01 | atropin (do 1mg v 1 ampuli) | parent. | 1.50 | MG | 14,81 | |
|
| 5.5 | A03BB01 | butylskopolamin | p.rect. | 60.00 | MG | 14,33 | |
|
| 5.6 | A03BB01 | butylskopolamin | parent. | 60.00 | MG | 36,77 | |
|
| 6 | anticholinergika a spasmolytika v kombinaci s analgetiky |
|
| 6.1 | A03DA | syntetická anticholinergika v komb. s analgetiky | p.o. | 2.00 | DF | 3,87 | |
|
| 6.2 | A03DA02 | pitofenon kombinace s analgetiky | p.rect. | 2.00 | DF | 13,29 | |
| 91517 | ALGIFEN SUP | rct sup 5 | LEX | CZ |
| 6.3 | A03DA02 | pitofenon kombinace s analgetiky | parent. | 2.00 | DF | 43,25 | |
|
| 6.4 | A03DA02 | pitofenon kombinace s analgetiky (pevné lékové formy) | p.o. | 2.00 | DF | 4,02 | |
|
| 6.5 | A03DA02 | pitofenon kombinace s analgetiky (tekuté lékové formy) | p.o. | 2.00 | ML | 5,69 | |
|
| 6.6 | A03EA | antispasmodika, psycholeptika, analgetika v komb. | p.rect. | 2.00 | DF | 12,43 | |
|
| 7 | prokinetika, antiflatulencia, perorální podání |
|
| 7.1 | A03AE02 | tegaserod | p.o. | 12.00 | MG | 29,32 | |
|
| 7.2 | A03AX13 | silikony (pevné lékové formy) | p.o. | 0.50 | GM | 10,66 | |
|
| 7.3 | A03AX13 | silikony (tekuté lékové formy) | p.o. | 0.50 | GM | 18,15 | |
| 93500 | SAB SIMPLEX | sus 1x30ml | PDA | D |
| 7.4 | A03AX58 | alverin (kombinace se silikony) | p.o. | 0.18 | GM | 7,72 | |
| |
| 7.5 | A03FA | itoprid | p.o. | 0.15 | GM | 26,00 | L/GIT,INT,PED |
| |
| 7.6 | A03FA01 | metoclopramid hydrochlorid | p.o. | 30.00 | MG | 3,87 | |
| 56695 | MCP HEXAL 10 | tbl 50x10mg | SFS | D |
| 56696 | MCP HEXAL 10 | tbl 100x10mg | SFS | D |
| 7.7 | A03FA02 | cisaprid (pevné lékové formy, nad 10 mg v 1 tabletě) | p.o. | 30.00 | MG | 21,99 | L/GIT,INT,PED PSY, GER |
| |
| 7.8 | A03FA02 | cisaprid (pevné lékové formy, nad 5 mg do 10 mg včetně v 1 tabletě) | p.o. | 30.00 | MG | 25,41 | L/GIT,INT,PED PSY, GER |
| |
| 7.9 | A03FA02 | cisaprid (tekuté lékové formy dělené -sáčky) | p.o. | 30.00 | MG | 25,41 | L/GIT,INT,PED PSY, GER |
| |
| 7.10 | A03FA02 | cisaprid (tekuté lékové formy) s obsahem 1 mg v 1 ml | p.o. | 30.00 | MG | 55,88 | L/GIT,INT,PED PSY, GER |
| |
| 7.11 | A03FA03 | domperidon | p.o. | 30.00 | MG | 3,87 | |
| |
| 7.12 | A03FA05 | alizaprid | p.o. | 0.15 | GM | 3,87 | |
| |
| 8 | prokinetika, ostatní cesty aplikace |
| |
| 8.1 | A03FA01 | metoclopramid | p.rect. | 30.00 | MG | 40,56 | |
| |
| 8.2 | A03FA01 | metoclopramid | parent. | 30.00 | MG | 20,80 | O |
| 93105 | DEGAN | inj 50x2ml/10mg | LEK | SLO |
| 8.3 | A03FA02 | cisaprid | p.rect. | 30.00 | MG | 46,49 | |
| |
| 8.4 | A03FA03 | domperidon | p.rect. | 0.12 | GM | 40,56 | |
| |
| 8.5 | A03FA05 | alizaprid | parent. | 0.15 | GM | 16,10 | O |
| |
| 9 | antiemetika, perorální podání |
| |
| 9.1 | A04AA01 | ondansetron (pevné lékové formy do 4 mg v jedné tabletě včetně) | p.o. | 16.00 | MG | 471,01 | P |
| 15829 | EMESET- 4 | por tbl flm 6x4mg | SDD | CZ |
| 15830 | EMESET- 4 | por tbl flm 60x4mg | SDD | CZ |
| 84744 | EMESET- 4 | tbl obd 6x4mg | CIA | IND |
| 9.2 | A04AA01 | ondansetron (pevné lékové formy nad 4 mg v jedné tabletě) | p.o. | 16.00 | MG | 349,09 | P |
| 15831 | EMESET- 8 | por tbl flm 6x8mg | SDD | CZ |
| 9.3 | A04AA01 | ondansetron (tekuté lékové formy) | p.o. | 16.00 | MG | 737,52 | P |
| |
| 9.4 | A04AA02 | granisetron | p.o. | 2.00 | MG | 349,09 | P |
| |
| 9.5 | A04AA03 | tropisetron | p.o. | 5.00 | MG | 349,09 | P |
| |
| 9.6 | A04AA04 | dolasetron | p.o. | 200.00 | MG | 349,09 | P |
Ondansetron, granisetron, tropisetron and dolasetron are paid for in patients with nausea and vomiting due to strong serotonin release, i. e. induced by cytotoxic chemotherapy and radiotherapy.
| 9.7 | A04AD | různá antiemetika (meklozin) | p.o. | 50.00 | MG | 3,23 | |
| |
| 9.8 | A04AD | různá antiemetika (theoklát embraminu) | p.o. | 50.00 | MG | 3,23 | |
| |
| 9.9 | A04AD | různá antiemetika (theoklát moxastinu) | p.o. | 0.10 | GM | 3,23 | |
| |
| 10 | antiemetika, ostatní cesty aplikace |
| |
| 10.1 | A04AA | palonosetron | parent. | 1 | DF | 2 834,17 | P |
| |
| 10.2 | A04AA01 | ondansetron (léková forma čípků) | p.rect. | 16.00 | MG | 570,74 | P |
| |
| 10.3 | A04AA01 | ondansetron (do 4 mg v jedné ampuli včetně) | parent. | 16.00 | MG | 787,83 | P |
| 15827 | EMESET | inj sol 5x2ml/4mg | SDD | CZ |
| 84441 | EMESET | inj 5x2ml/4mg | CIA | IND |
| 10.4 | A04AA01 | ondansetron (nad 4 mg v jedné ampuli) | parent. | 16.00 | MG | 635,40 | P |
| 15828 | EMESET | inj sol 5x4ml/8mg | SDD | CZ |
| 10.5 | A04AA02 | granisetron | parent. | 3.00 | MG | 417,11 | P |
| |
| 10.6 | A04AA03 | tropisetron (do 2,5 mg včetně v jedné ampuli) | parent. | 5.00 | MG | 717,91 | P |
| |
| 10.7 | A04AA03 | tropisetron (nad 2,5 mg v jedné ampuli) | parent. | 5.00 | MG | 417,11 | P |
| |
| 10.8 | A04AA04 | dolasetron | parent. | 100.00 | MG | 417,11 | P |
Ondansetron, granisetron, tropisetron, dolasetron and palonosetron are paid for in patients with nausea and vomiting due to strong release of serotonin, i. e. induced by cytotoxic chemotherapy and radiotherapy.
| 10.9 | A04AD01 | různá antiemetika (theoklát moxastinu) | p.rect. | 0.10 | GM | 9,17 | |
| |
| 11 | hepatika a hepatoprotektiva a další léčiva působící na žlučové cesty nebo játra |
| |
| 11.1 | A05AA01 | kyselina chenodeoxycholová | p.o. | 1.00 | GM | 20,97 | L/GIT, INF |
| |
| 11.2 | A05AA02 | kyselina ursodeoxycholová | p.o. | 0.75 | GM | 23,20 | L/GIT,INF |
| 13808 | URSOSAN | por cpsdur100x250mg | PMP | CZ |
| 11.3 | A05AX | jiná léčiva onemocnění žlučníku (fenipentol) | p.o. | 3.00 | DF | 1,58 | |
| |
| 11.4 | A05AX02 | hymekromon | p.o. | 1.20 | GM | 5,82 | |
| |
| 11.5 | A05BA | léčiva onemocnění jater (fosfolipidy) | p.o. | 4.00 | DF | 11,46 | |
| |
| 11.6 | A05BA | léčiva onemocnění jater (fosfolipidy) | parent. | 1.00 | DF | 41,75 | H |
| |
| 11.7 | A05BA | léčiva onemocnění jater (silymarin v kombinaci) | p.o. | 0.21 | GM | 5,38 | |
| |
| 11.8 | A05BA03 | silymarin | parent. | 0.35 | GM | 2 291,90 | H |
| |
| 11.9 | A05BA03 | silymarin (do 70 mg včetně v jedné tabletě) | p.o. | 0.21 | GM | 5,38 | |
| |
| 11.10 | A05BA03 | silymarin (nad 70 mg v jedné tabletě) | p.o. | 0.21 | GM | 4,30 | |
| |
| 12 | laxativa a další léčiva k očištění střeva |
| |
| 12.1 | A06AD10 | kombinace minerálních solí (k přípravě Golytelyho roztoku) | p.o. | 4.00 | DF | 237,19 | |
| |
| 12.2 | A06AD11 | laktulóza | p.o. | 6.70 | GM | 4,40 | L/GIT,INT,GER, PED,CHI,ONK |
| 42547 | LACTULOSE AL SIRUP | por sir 1x500ml | APA | D |
| 81456 | DUPHALAC | por sir 1x500ml-hdp | SOO | NL |
| 12.3 | A06AD12 | laktitol | p.o. | 10.00 | GM | 3,63 | L/GIT,INT,GER, CHI |
| |
| 12.4 | A06AD15 | macrogol | p.o. | 4.00 | DF | 237,19 | |
| |
| 12.5 | A06AG10 | sorbitol v kombinaci s kont. laxativem | p.rect. | 2.00 | DF | 170,06 | |
| 92489 | YAL | sol 10x67.5ml | TRM | D |
| 13 | antidiarhoika, antiinfekční a protizánětlivá léčiva gastrointestinálního traktu, perorální podání |
| |
| 13.1 | A07AA01 | neomycin | p.o. | 5.00 | GM | 596,07 | H |
| |
| 13.2 | A07AA02 | nystatin | p.o. | 1.50 | MU | 5,82 | |
| |
| 13.3 | A07AA03 | natamycin | p.o. | 0.30 | GM | 40,08 | |
| |
| 13.4 | A07AA11 | rifaximin | p.o. | 0.80 | GM | 83,07 | P |
Rifaximin is indicated in the following cases:
(1) hepatic encephalopathy,
2) prophylaxis in colorectal surgery,
3) pseudomembranose colitis,
4) bacterial infection associated with non-specific inflammatory diseases of the bowel (Crohn 's disease and ulcerative colitis) susceptible to rifaximin,
5) Demonstrated colon diverticulitis susceptible to rifaximin.
| 13.5 | A07BC05 | diosmectit (plv. susp.) | p.o. | 1.00 | DF | 3,77 | L/PED, INF |
| |
| 13.6 | A07EA06 | budesonid | p.o. | 9.00 | MG | 101,44 | P |
Treatment with oral budesonide is prescribed by a gastro-enterologist or an intern in an acute attack or chronic phase of Crohn 's disease, particularly where the need for steroid treatment is created and the need to minimise their systemic effects.
| 64786 | BUDENOFALK | cps ent 50x3mg | FAK | D |
| 13.7 | A07EB01 | natrium kromoglykát | p.o. | 800.00 | MG | 71,91 | P |
Treatment with cromoglycate is prescribed by an allergologist and a clinical immunologist, based on an allergological examination of skin potential exposure tests or evidence of specific IgE antibodies and with proven food allergy with severe local or overall symptoms that cannot be fully corrected by elimination of food allergens.
| 13.8 | A07EC01 | sulfasalazin | p.o. | 2.00 | GM | 14,80 | L/GIT,INT,REV, GER |
| |
| 13.9 | A07EC02 | mesalazin (léková forma - sáčky) | p.o. | 1.50 | GM | 43,12 | P |
Mesalazine per os - pharmaceutical forma-sachets: is an aminosalicylate of first choice for idiopathic intestinal inflammation (Crohn 's disease) affecting the upper part of the digestive tract, small intestine and adjacent parts of the colon (ileocolitis) in children under 3 years of age and in patients with swallowing disorder. It is not a first-choice aminosalicylate for the location of idiopathic intestinal inflammation in the colon; is indicated after failure of other aminosalicylates.
| 13.10 | A07EC02 | mesalazin (potahované tablety) | p.o. | 1.50 | GM | 22,56 | L/GIT,INT,GER |
| 15533 | ASACOL 400 | por tblflm100x400mg | MBO | CZ |
| 13.11 | A07EC02 | mesalazin (tablety s řízeným uvolňováním) | p.o. | 1.50 | GM | 40,95 | P |
Mesalazine powder - modified-release tablets: is a first-choice aminosalicylate in idiopathic intestinal inflammation (Crohn 's disease) affecting the upper gastrointestinal tract, small intestine and adjacent colon (ileocolitis). It is not a first-choice aminosalicylate for the location of idiopathic intestinal inflammation in the colon, it is indicated here after failure of other aminosalicylates.
| 13.12 | A07FA | protiprůjmové mikroorganismy (Escherichia coli), lékové formy tobolek | p.o. | 2.00 | DF | 24,57 | P |
It is covered by maintenance treatment in non-specific intestinal inflammation.
| 66065 | MUTAFLOR 20MG | cps ent 20x20mg | ARP | D |
| 13.13 | A07FA | protiprůjmové mikroorganismy (Escherichia coli), tekuté lékové formy | p.o. | 1.00 | DF | 42.99 | L/PED, INF |
| |
| 13.14 | A07FA01 | organismy produkující kyselinu mléčnou, pevné lékové formy | p.o. | 4.00 | DF | 3,77 | L/PED,GIT,GER, INF |
| |
| 13.15 | A07FA01 | organismy produkující kyselinu mléčnou, tekuté lékové formy | p.o. | 2.00 | ML | 3,47 | L/PED,GIT,GER, INF |
| 09159 | HYLAK FORTE | sol 1x100ml | MCK | D |
| 13.16 | A07FA02 | saccharomyces boulardii sicatus | p.o. | 1.00 | DF | 5,38 | P |
Preparations containing saccharomyces boulardii sic. are indicated in infectious diarrhoea, prophylaxis and treatment of diarrhoea in patients fed with gastric or enteral nutrition using a probe.
| 14 | antidiarhoika, antiinfekční a protizánětlivá léčiva gastrointestinálního traktu, ostatní cesty aplikace |
| |
| 14.1 | A07EA06 | budesonid | p.rect. | 2.00 | MG | 244,33 | L/GIT,INT,GER |
| |
| 14.2 | A07EC | paraaminosalicylát sodný | p.rect. | 2.00 | GM | 45,15 | L/GIT |
| |
| 14.3 | A07EC02 | mesalazin (čípky do 250 mg včetně) | p.rect. | 1.50 | GM | 108,77 | L/GIT |
| |
| 14.4 | A07EC02 | mesalazin (čípky nad 250 mg) | p.rect. | 1.50 | GM | 93,87 | L/GIT |
| |
| 14.5 | A07EC02 | mesalazin (enm.) | p.rect. | 1.50 | GM | 66,73 | L/GIT |
| 15535 | ASACOL ENEMA 4 G | sus rec 1x100ml/4gm | MBO | CZ |
| 15536 | ASACOL ENEMA 4 G | sus rec 7x100ml/4gm | MBO | CZ |
| 15 | digestiva včetně enzymových přípravků |
| |
| 15.1 | A09AA | enzymové přípravky (s pankreatinem, dle obsahu lipázy) | p.o. | 5 000.00 | U | 0,10 | |
| |
| 15.2 | A09AA02 | multienzymy (dle obsahu lipázy: do 10 000U včetně v jedné tabletě nebo kapsli) | p.o. | 5 000.00 | U | 1,44 | P |
Multienzymes up to 10,000 lipase In one tablet, cystic fibrosis is indicated for paediatric patients below 10 kg of their body weight.
| 15.3 | A09AA02 | multienzymy (dle obsahu lipázy: nad 10 000 do 19 999 U v jedné tabletě) | p.o. | 5 000.00 | U | 0,10 | |
| |
| 15.4 | A09AA02 | multienzymy (dle obsahu lipázy: 20 000U v jedné tabletě) | p.o. | 5 000.00 | U | 1,38 | P |
Multienzymes as gastro-resistant tablets containing 20,000 lipase In one tablet, patients with established algic form of chronic pancreatitis are indicated using at least one of the following methods: ERCP, EUS, CT, MRCP, peroperatively, pancreatic cancer patients and pancreatic resection patients.
| 40378 | PANZYNORM FORTE-N | por tbl flm 30 | KRK | SLO |
| 40379 | PANZYNORM FORTE-N | por tbl flm 100 | KRK | SLO |
| 15.5 | A09AA02 | multienzymy (dle obsahu lipázy: nad 20000U v jedné tabletě) – formy mikropelet | p.o. | 5 000.00 | U | 1,91 | P |
Micropellet multienzymes are indicated in patients with cystic fibrosis and proven chronic pancreatitis using at least one of the following methods: ERCP, EUS, CT, MRCP, pancreatic cancer patients and pancreatic resection patients.
| 14811 | KREON 25 000 | por cps dur 50 | SVP | D |
| 15.6 | A09AA02 | multienzymy (dle lipázy, nad 20.000 U v jedné tabletě) | p.o. | 5 000.00 | U | 0,10 | |
| |
| 15.7 | A09AC01 | pepsin a kyselinotvorné látky | p.o. | 2.00 | DF | 0,10 | |
| |
| 16 | insuliny krátkodobě působící |
| |
| 16.1 | A10AB01 | insulin lidský rychle účinkující 100 U/ml, cartridge | parent. | 40.00 | U | 21,50 | L/DIA |
| |
| 16.2 | A10AB01 | insulin lidský rychle účinkující 100 U/ml, cartridge v jednorázovém aplikátoru | parent. | 40.00 | U | 26,00 | P |
Diabetes mellitus treated with insulin in patients with defined visual impairment determined by ophthalmologist examination - a decrease in visual acuity below 0.4 on a better eye with optimal correction and at a value of visual acuity up to close of more than 10 Jg with optimal correction and proven not to use other applicators due to visual impairment.
| 16.3 | A10AB01 | insulin lidský rychle účinkující, lahv. | parent. | 40.00 | U | 16,29 | |
| 40876 | INSULIN-HM R | inj 1x10ml/1ku | ZEH | CZ |
| 16.4 | A10AB03 | insulin vepřový rychle účinkující - cartridge | parent. | 40.00 | U | 21,50 | L/DIA |
| |
| 16.5 | A10AB03 | insulin vepřový rychle účinkující - lahv. | parent. | 40.00 | U | 16,11 | |
| |
| 17 | insuliny střednědobě působící včetně kombinací |
| |
| 17.1 | A10AC02 | insulin hovězí středně dlouze účinkující -cartridge | parent. | 40.00 | U | 21,11 | L/DIA |
| |
| 17.2 | A10AC02 | insulin hovězí středně dlouze účinkující -lahv. | parent. | 40.00 | U | 11,72 | |
| |
| 17.3 | A10AC03 | insulin vepřový středně dlouze účinkující | parent. | 40.00 | U | 12,35 | |
| |
| 17.4 | A10AC30 | insulin kombinace zvířecí středně dlouze účinkující | parent. | 40.00 | U | 12,35 | |
| |
| 17.5 | A10AD01 | insulin lidský kombinace středně a rychle účinného 100U/ml, cartridge | parent. | 40.00 | U | 21,50 | L/DIA |
| |
| 17.6 | A10AD01 | insulin lidský kombinace středně a rychle účinného 100U/ml, cartridge v jednorázovém aplikátoru | parent. | 40.00 | U | 26,00 | P |
Diabetes mellitus treated with insulin in patients with defined visual impairment determined by ophthalmologist examination - a decrease in visual acuity below 0.4 on a better eye with optimal correction and at a value of visual acuity up to close of more than 10 Jg with optimal correction and proven not to use other applicators due to visual impairment.
| 17.7 | A10AD01 | insulin lidský kombinace středně a rychle účinného, lahv. | parent. | 40.00 | U | 16,29 | |
| 40878 | INSULIN-HM MIX 30 | inj 1x10ml/1ku | ZEH | CZ |
| 18 | insuliny dlouhodobě působící |
| |
| 18.1 | A10AC01 | insulin lidský středně dlouze účinkující 100U/ml, cartridge | parent. | 40.00 | U | 21,50 | L/DIA |
| |
| 18.2 | A10AC01 | insulin lidský středně dlouze účinkující 100U/ml, cartridge v jednorázovém aplikátoru | parent. | 40.00 | U | 26,00 | P |
Diabetes mellitus treated with insulin in patients with defined visual impairment determined by ophthalmologist examination - a decrease in visual acuity below 0.4 on a better eye with optimal correction and at a value of visual acuity up to close of more than 10 Jg with optimal correction and proven not to use other applicators due to visual impairment.
| 18.3 | A10AC01 | insulin lidský středně dlouze účinkující, lahv. | parent. | 40.00 | U | 16,29 | |
| 40875 | INSULIN-HM NPH | inj 1x10ml/1ku | ZEH | CZ |
| 18.4 | A10AE01 | insulin lidský dlouhodobě účinkující | parent. | 40.00 | U | 16,29 | |
| |
| 18.5 | A10AE02 | insulin hovězí dlouhodobě účinkující -lahv. | parent. | 40.00 | U | 11,72 | |
| |
| 18.6 | A10AE30 | insulin kombinace zvířecí dlouhodobě účinkující | parent. | 40.00 | U | 12,35 | |
| |
| 19 | analoga insulinů a insuliny používané k aplikaci pomocí insulinové pumpy |
| |
| 19.1 | A10AB04 | insulin-lispro krátce působící, cartridge 100U/ML | parent. | 40.00 | U | 28,30 | P |
| |
| 19.2 | A10AB04 | insulin-lispro krátce působící, lahv. | parent. | 40.00 | U | 27,64 | |
| |
| 19.3 | A10AB05 | insulin-aspart krátce působící, cartridge 100U/ML | parent. | 40.00 | U | 28,30 | P |
| |
| 19.4 | A10AB05 | insulin-aspart krátce působící, lahv. | parent. | 40.00 | U | 27,64 | |
| |
| 19.5 | A10AB06 | insulin glulisin, cartridge 100U/ML | parent. | 40.00 | U | 28,30 | P |
Insulin analogues (insulin aspart, insulin lispro, insulin glulisine) are indicated in patients who lead to a demonstrable improvement in glycaemic control compared to conventional human insulin, i. e. where they make the mean HbA1c decrease by at least 10% and therefore lead to an improvement in glycaemic profiles, including a reduction in the frequency of hypoglycaemia.
| 19.6 | A10AB01 | insulin lidský rychle účinkující pro aplikaci do insulínových pump | parent. | 40.00 | U | 27,60 | L/DIA |
| 28001 | VELOSULIN 100 IU/ML | inj sol 1x10ml/1ku | NOO | DK |
| 19.7 | A10AD05 | insulin aspart, kombinace středně a rychle účinného, cartridge | parent. | 40.00 | U | 28,30 | P |
| |
| 19.8 | A10AE04 | insulin glargin, dlouhodobě účinný, lahv. | parent. | 40.00 | U | 21,50 | L/DIA |
| |
| 19.9 | A10AE04 | insulin glargin, dlouhodobě účinný, cartridge | parent. | 40.00 | U | 45,49 | P |
| |
| 19.10 | A10AE05 | insulin detemir, dlouhodobě účinný, cartridge | parent. | 40.00 | U | 45,49 | P |
Long-acting insulin analogues are prescribed only in patients treated with diabetes mellitus or outpatient diabetes mellitus on the recommendation of the diabetes centre for whom treatment with an insulin pump is indicated (repeated hypoglycaemia, dilated diabetes with unsatisfactory compensation, requiring long-term effective insulin multiple times daily).
| 20 | perorální antidiabetika ze skupiny biguanidů a glitazonů |
| |
| 20.1 | A10BA02 | metformin hydrochlorid | p.o. | 2.00 | GM | 5,98 | |
| 06668 | METFIREX 500 MG | por tbl flm60x500mg | CHN | H |
| 23228 | METFIREX 1 G | por tblflm60x1000mg | CPW | H |
| 30294 | ADIMET | tbl obd 60x850mg | MCK | D |
| 30343 | METFORMIN AL 500 | por tbl flm30x500mg | APA | D |
| 30356 | METFORMIN AL 500 | por tbl flm60x500mg | APA | D |
| 30361 | METFORMIN AL 500 | por tblflm120x500mg | APA | D |
| 40001 | METFORMIN AL 850 | por tbl flm30x850mg | APA | D |
| 40155 | METFORMIN AL 850 | por tbl flm60x850mg | APA | D |
| 40174 | METFORMIN AL 850 | por tblflm120x850mg | APA | D |
| 41506 | METFIREX 850 MG | por tblflm120x850mg | CHN | H |
| 41507 | METFIREX 500 MG | por tblflm120x500mg | CHN | H |
| 58122 | DIAPHAGE 850 | por tbl flm50x850mg | SVS | CZ |
| 58123 | DIAPHAGE 850 | por tblflm100x850mg | SVS | CZ |
| 58124 | DIAPHAGE 500 | por tblflm100x500mg | SVS | CZ |
| 58125 | DIAPHAGE 500 | por tbl flm50x500mg | SVS | CZ |
| 64641 | ADIMET | tbl obd 30x850mg | MCK | D |
| 64642 | ADIMET | tbl obd 120x850mg | MCK | D |
| 20.2 | A10BA03 | buformin | p.o. | 0.20 | GM | 3,39 | |
| |
| 20.3 | A10BD02 | metformin a glibenklamid - kombinace | p.o. | 3.00 | DF | 4,84 | |
| |
| 20.4 | A10BD03 | metformin a roziglitazon v kombinaci 500 mg a 1 mg | p.o. | 1.00 | DF | 10,02 | P |
| |
| 20.5 | A10BD03 | metformin a roziglitazon v kombinaci 500 mg a 2 mg | p.o. | 1.00 | DF | 18,57 | P |
| |
| 20.6 | A10BD03 | metformin a roziglitazon v kombinaci 1000 mg a 2 mg | p.o. | 1.00 | DF | 20,03 | P |
Metformin and rosiglitazone in combination are indicated for the treatment of patients with type 2 diabetes and overweight (BMI greater than 25 kg / m2) and insufficient compensation for previous metformin therapy of at least 2 g daily (HbA1c greater than 6.0% / according to IFCC).
| 20.7 | A10BF01 | akarboza | p.o. | 0.30 | GM | 10,03 | |
| |
| 20.8 | A10BG02 | rosiglitason s obsahem 4 mg v jedné tabletě | p.o. | 1.00 | DF | 34,21 | P |
| |
| 20.9 | A10BG03 | pioglitazon s obsahem 15 mg v jedné tabletě | p.o. | 1.00 | DF | 34,21 | P |
| |
| 20.10 | A10BG03 | pioglitazon s obsahem 30 mg v jedné tabletě | p.o. | 1.00 | DF | 40,66 | P |
Thiazolidinedione derivatives are prescribed by a type 2 diabetes specialist for the treatment of patients with type 2 diabetes and overweight or obesity (BMI > 25 kg / m2), with insulin resistance expressed under conditions of repeated evidence of insufficient treatment compensation (HbA1c > 6.0% / according to IFCC). The indicated daily dose is 1 tbl of 4 mg rosiglitazone, or 1 tbl of 15 mg or 1 tablet of 30 mg pioglitazone.
| 21 | perorální antidiabetika ze skupiny sulfonylurey a meglitinidů, případně další antidiabetika |
| |
| 21.1 | A10BB01 | glibenklamid (do 1 mg v jedné tabletě včetně) | p.o. | 10.00 | MG | 2,25 | |
| |
| 21.2 | A10BB01 | glibenklamid (nad 1 mg v jedné tabletě) | p.o. | 10.00 | MG | 0,84 | |
| |
| 21.3 | A10BB01 | glibenklamid (mikronizované formy, do 1,75 mg včetně v jedné tabletě) | p.o. | 7.00 | MG | 1,34 | |
| 94523 | GLUCOBENE 1.75 MG | tbl 120x1.75mg | MCK | D |
| 21.4 | A10BB01 | glibenklamid (mikronizované formy, nad 1,75 mg v jedné tabletě) | p.o. | 7.00 | MG | 0,84 | |
| 94525 | GLUCOBENE 3.5 MG | tbl 120x3.5mg | MCK | D |
| 21.5 | A10BB02 | chlorpropamid | p.o. | 0.37 | GM | 0,76 | |
| |
| 21.6 | A10BB03 | tolbutamid | p.o. | 1.50 | GM | 2,27 | |
| |
| 21.7 | A10BB04 | glibornurid | p.o. | 38.00 | MG | 4,68 | |
| |
| 21.8 | A10BB05 | tolazamid | p.o. | 1.00 | GM | 2,43 | |
| |
| 21.9 | A10BB07 | glipizid | p.o. | 10.00 | MG | 3,71 | |
| |
| 21.10 | A10BB08 | gliquidon | p.o. | 60.00 | MG | 5,52 | |
| |
| 21.11 | A10BB09 | gliklazid | p.o. | 0.16 | GM | 5,77 | |
| 31897 | GLICIREX | por tbl nob 60x80mg | RTT | D |
| 21.12 | A10BB09 | gliklazid, retardované lékové formy | p.o. | 2.00 | DF | 5,77 | |
| |
| 21.13 | A10BB12 | glymepirid do 2 mg v jedné tabletě včetně | p.o. | 2.00 | MG | 5,77 | |
| |
| 21.14 | A10BB12 | glymepirid nad 2 mg v jedné tabletě | p.o. | 2.00 | MG | 4,79 | |
| |
| 21.15 | A10BX02 | repaglinid | p.o. | 1.00 | DF | 4,89 | L/DIA |
| |
| 21.16 | A10BX03 | nateglinid | p.o. | 1.00 | DF | 4,89 | L/DIA |
| |
| 22 | vitamin A nebo D včetně jejich kombinací, perorální podání |
| |
| 22.1 | A11CA01 | retinol (vitamin A) | p.o. | 50.00 | KU | 1,09 | |
| |
| 22.2 | A11CC01 | ergocalciferol (pevné lékové formy) | p.o. | 6.00 | KU | 0,53 | |
| 00353 | VITAMIN D SLOVAKOFARMA | cps 1x300ku | SLO | SK |
| 22.3 | A11CC01 | ergokalciferol (tekuté lékové formy, do 200 U/ml včetně) | p.o. | 6.00 | KU | 12,80 | |
| |
| 22.4 | A11CC01 | ergokalciferol (tekuté lékové formy, nad 200 U/ml) | p.o. | 6.00 | KU | 0,76 | |
| 00716 | INFADIN | gtt 1x10ml/100mg | SLO | SK |
| 22.5 | A11CC02 | dihydrotachysterol | p.o. | 1.00 | MG | 16,74 | |
| |
| 22.6 | A11CC03 | alfakalcidol do 0,50 rg včetně | p.o. | 1.00 | RG | 15,44 | P |
| |
| 22.7 | A11CC03 | alfakalcidol nad 0,50 rg | p.o. | 1.00 | RG | 14,56 | P |
| |
| 22.8 | A11CC04 | kalcitriol | p.o. | 1.00 | RG | 29,15 | P |
Treatment with alfacalcidol and calcitriol is prescribed by an internist, an endocrinologist, a urologist, a pediatrician and a physician in the dialysis unit in patients:
(a) a senile or osteoporotic fracture which has developed during vitamin D and calcium-free therapy;
(b) induced by the treatment of glucocorticoids,
(c) at a high dose of corticosteroids (7,5 mg prednisone daily and greater) with elevated PTH levels resistant to vitamin D and calcium therapy.
2. For the treatment of renal osteodystrophy with chronic renal insufficiency (particularly in patients on dialysis).
3. With vitamin D resistance.
4. Vitamin D resistant osteomalacia.
5. With hypoparathyroidism or pseudo-hypoparathyroidism resistant to vitamin D and calcium treatment.
| 22.9 | A11CC05 | cholekalciferol - pevné lékové formy | p.o. | 0.50 | MG | 1,02 | |
|
| 22.10 | A11CC05 | cholekalciferol – tekuté lékové formy | p.o. | 0.50 | MG | 3,75 | |
| 12023 | VIGANTOL | por gtt sol 1x10ml | MEC | D |
| 23 | vitamin A nebo D včetně jejich kombinací, ostatní cesty aplikace |
| |
| 23.1 | A11CA01 | retinol (vitamin A) | parent. | 50.00 | KU | 10,16 | |
| |
| 23.2 | A11CC | paricalcitolum | parent. | 2.50 | RG | 376,26 | O/P |
Paricalcitol treatment is indicated if:
(a) the serum PHT concentration is greater than 400pg / ml despite treatment with calcitriol for 3 months;
(b) calcitriol (hypercalcaemia on calcitriol - greater than 2,7 mmol / l and hyperphosphatemia greater than 2,5 mmol / l; phosphocalcatic product greater than 6,5) fails,
(c) extraoseal calcification with advanced hyperparathyroidism).
The treatment condition is:
(a) sonographically proven enlarged parathyroid organs,
(b) verified hemodialysis efficacy (Kt / V above 1,2);
(c) compliance of the patient with measures regulating serum phosphorus concentrations (dietotherapy, effective dialysis, preparation of phosphate binders in GIT.
| 16881 | ZEMPLAR 5 MCG/ML | inj sol 5x2ml | ABB | I |
| 23.3 | A11CC01 | ergokalciferol | parent. | 6.00 | KU | 0,70 | |
| |
| 23.4 | A11CC04 | kalcitriol | parent. | 1.00 | RG | 170,25 | P |
Treatment with parenteral calcitriol is prescribed by an internist, an endocrinologist, a urologist, a pediatrician and a physician in the dialysis unit in patients:
(a) a senile or osteoporotic fracture which has developed during vitamin D and calcium-free therapy;
(b) induced by the treatment of glucocorticoids,
(c) at a high dose of corticosteroids (7,5 mg prednisone daily and greater) with elevated PTH levels resistant to vitamin D and calcium therapy.
2. For the treatment of renal osteodystrophy with chronic renal insufficiency (particularly in patients on dialysis).
3. With vitamin D resistance.
4. Vitamin D resistant osteomalacia.
5. With vitamin D and calcium-resistant hypoparathyroidism.
| 23.5 | A11CC05 | cholekalciferol | parent. | 1.00 | KU | 0,92 | |
| 11093 | VIGANTOL 50000 | inj 5x1ml/1.25mg | MEC | D |
| 24 | soli vápníku, perorální podání |
| |
| 24.1 | A12AA03 | glukonát vápenatý (na obsah vápníku) | p.o. | 0.50 | GM | 0,58 | |
| |
| 24.2 | A12AA04 | uhličitan vápenatý (na obsah vápníku) tablety | p.o. | 0.50 | GM | 2,29 | |
| 70536 | TBL.CALCII CARBON.PRAEC.0.5 MVM | portblnob1000x0.5gm | MVM | CZ |
| 24.3 | A12AA04 | uhličitan vápenatý (na obsah vápníku), léková forma šumivé tablety | p.o. | 0.50 | GM | 2,29 | |
|
| 24.4 | A12AA04 | uhličitan vápenatý(na obsah vápníku), léková forma prášky | p.o. | 0.50 | GM | 2,29 | |
|
| 24.5 | A12AA07 | chlorid vápenatý (na obsah vápníku), tekuté lékové formy, | p.o. | 0.20 | GM | 0,63 | |
|
| 24.6 | A12AA12 | octan vápenatý (na obsah vápníku) | p.o. | 0.50 | GM | 9,77 | |
|
| 25 | kombinace solí vápníku, perorální podání |
|
| 25.1 | A12AA20 | vápník (kombinace různých solí, na obsah vápníku) | p.o. | 0.50 | GM | 2,48 | |
|
| 25.2 | A12AX | uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) do 600 mg vápníku v 1 dávce včetně a do 5 mg cholekalciferolu v 1 dávce včetně | p.o. | 1.00 | DF | 3,19 | |
|
| 25.3 | A12AX | uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) do 600 mg vápníku v 1 dávce včetně a nad 5 mg cholekalciferolu v 1 dávce | p.o. | 1.00 | DF | 3,91 | |
|
| 25.4 | A12AX | uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) nad 600 mg vápníku v 1 dávce | p.o. | 1.00 | DF | 6,36 | |
|
| 25.5 | A12AX | vápník v kombinaci s fluorem (fluorofosfat sodný) | p.o. | 1.00 | DF | 5,26 | L/INT,GYN,ORT, REV,GER |
|
| 25.6 | A12AX | vápník v kombinaci s fluorem (levoglutamid fluorofosfat) | p.o. | 1.00 | DF | 3,92 | L/INT,GYN,ORT, REV,GER |
|
| 25.7 | A12CX | jiné minerální produkty (na obsah vápníku) | p.o. | 0.50 | GM | 1,16 | |
| 99808 | BIOMIN H | plv 60x3gm(sÁČky) | BMN | SK |
| 26 | soli vápníku, ostatní cesty aplikace |
| |
| 26.1 | A12AA03 | glukonát vápenatý (na obsah vápníku) | parent. | 3.00 | GM | 57,82 | |
| |
| 26.2 | A12AA07 | chlorid vápenatý (na obsah vápníku) | parent. | 0.20 | GM | 2,91 | |
| 00409 | CALCIUM CHLORATUM BIOTIKA | inj 5x10ml 10% | HBS | SK |
| 27 | soli draslíku, perorální podání |
| |
| 27.1 | A12BA | draslík (na obsah draslíku) | p.o. | 1.50 | GM | 2,38 | |
| |
| 27.2 | A12BA | draslík v kombinaci s hořčíkem (na obsah draslíku) | p.o. | 1.00 | GM | 9,56 | |
| |
| 27.3 | A12BA01 | chlorid draselný (na obsah chloridu draselného) | p.o. | 3.00 | GM | 2,32 | |
| 13715 | KALNORMIN | por tbl pro 30x1gm | ICN | H |
| 28 | soli draslíku, ostatní cesty aplikace |
| |
| 28.1 | A12BA | draslík v kombinaci s hořčíkem | parent. | 1.00 | DF | 12,90 | O |
| 02132 | CARDILAN | inj 10x10ml | HBS | SK |
| 28.2 | A12BA | draslík v kombinaci s hořčíkem, léková forma infuzí | parent. | 250.00 | ML | 84,05 | O |
| |
| 28.3 | A12BA01 | chlorid draselný (na obsah chloridu draselného) | parent. | 3.00 | GM | 52,24 | O |
| 02486 | KALIUM CHLORATUM LÉČIVA 7.5% | inj 5x10ml 7.5% | ZEH | CZ |
| 29 | soli hořčíku a jiné minerální produkty, perorální podání |
|
| 29.1 | A12CC03 | glukonat hořečnatý (na obsah hořčíku) | p.o. | 1.00 | GM | 11,12 | L/INT,NEU,PSY, GYN,GER |
|
| 29.2 | A12CC04 | citronan hořečnatý (na obsah hořčíku) | p.o. | 1.00 | GM | 11,12 | L/INT,NEU,PSY, GYN,GER |
|
| 29.3 | A12CC05 | aspartat hořečnatý (na obsah hořčíku) | p.o. | 1.00 | GM | 11,12 | L/INT,NEU,PSY, GYN,GER |
|
| 29.4 | A12CC06 | mléčnan hořečnatý (na obsah hořčíku) | p.o. | 1.00 | GM | 11,12 | L/INT,NEU,PSY, GYN,GER |
|
| 29.5 | A12CC09 | orotat hořečnatý (na obsah hořčíku) | p.o. | 1.00 | GM | 11,12 | L/INT,NEU,PSY, GYN,GER |
|
| 29.6 | A12CC30 | kombinace hořečnatých solí (na obsah hořčíku) | p.o. | 1.00 | GM | 11,12 | L/INT,NEU,PSY, GYN,GER |
| 18774 | MAGNESIUM 250 MG PHARMAVIT | por tbl eff 20 | BSQ | F |
| 99891 | MAGNESIUM 250 MG PHARMAVIT | por tbl eff 20 | CPW | H |
| 30 | soli hořčíku, ostatní cesty aplikace |
| |
| 30.1 | A12CC02 | síran hořečnatý (koncentrace do 10 % včetně) | parent. | 1.00 | GM | 19,27 | O |
| |
| 30.2 | A12CC02 | síran hořečnatý (koncentrace nad 10%) | parent. | 1.00 | GM | 9,07 | O |
| 00499 | MAGNESIUM SULFURICUM BIOT.20% | inj 5x10ml 20% | HBS | SK |
| 31 | soli fluoru, perorální podání |
| |
| 31.1 | A12CD01 | fluorid sodný | p.o. | 88.00 | MG | 5,16 | |
| 91080 | FLUOSSEN | por tbl ent 30x15mg | ICN | PL |
| 32 | ostatní léčiva ovlivňující trávicí systém |
| |
| 32.1 | A08AA10 | sibutramin s obsahem 10 mg v jedné tabletě | p.o. | 15.00 | MG | 48,87 | P |
| |
| 32.2 | A08AA10 | sibutramin s obsahem 15 mg v jedné tabletě | p.o. | 15.00 | MG | 36,84 | P |
Sibutramine prescribes diabetic patients with inadequately controlled type 2 diabetes mellitus (glycohemoglobin > 6% / according to IFCC) and concomitantly with BMI > 35 kg / m2 who are diagnosed with diabetic dyslipidaemia requiring pharmacological treatment. The contraindication is ICHS or blood pressure above 145 / 90. Sibutramine can only be prescribed to patients who reduce their weight by 3 kg over a 6-week period using only the regimen (diet and motion) measures. Tolerance should be evaluated every 14 days after initiation of therapy (blood pressure and heart rate) for 3 months, efficacy after 3 months of treatment with sibutramine. Efficacy criteria for sibutramine therapy are a weight decrease of at least 5% of baseline body weight while improving glycaemic control (fasting glucose or a decrease of at least 0,5% of HbA1c). If treatment is not effective, sibutramine is discontinued after 3 months. Sibutramine therapy is indicated for a maximum of 12 months.
| 32.3 | A08AB01 | orlistat | p.o. | 360.00 | MG | 36,84 | P |
Diabetologist prescribes orlistat for the treatment of obese type 2 and BMI patients above 35 kg / m2 with concurrently diagnosed arterial hypertension and / or dyslipidaemia and / or ischaemic heart disease in whom diabetes is not satisfactorily compensated (HbA1c above 6.0% / IFCC) with existing antidiabetic medication. Orlistat can only be prescribed for patients who reduce their weight by 3 kg over a 6-week period using only the regimen (diet and motion) measures. Efficacy of orlistat therapy is checked after 3 months, the criterion being improved glycaemic control (fasting glucose or a decrease in HbA1c of at least 0,5% in absolute terms) and weight decrease of at least 5% of baseline body weight. If treatment is not effective, administration of orlistat is discontinued after 3 months. Treatment is indicated for a maximum of 12 months.
| 32.4 | A11GA01 | kyselina askorbová (vitamin C) | parent. | 0.20 | GM | 3,24 | H |
| |
| 32.5 | A14AB01 | nandrolon phenpropionát | parent. | 2.00 | MG | 3,04 | |
| |
| 32.6 | A16AA01 | levokarnitin | parent. | 2.00 | GM | 348,72 | O |
| |
| 32.7 | A16AA02 | ademetionin | p.o. | 1.00 | GM | 58,47 | Z |
| |
| 32.8 | A16AA02 | ademetionin | parent. | 0.50 | GM | 92,51 | Z |
| 12319 | TRANSMETIL 500 MG INJEKCE | inj pso Iqf 5x500mg | HOL | I |
| 32.9 | A16AB02 | imiglucerasa | parent. | 200.00 | U | 39 426,04 | Z |
| 28018 | CEREZYME | inf plv sol 1x200ut | GZE | NL |
| 28020 | CEREZYME | inf plv sol 1x400ut | GZE | NL |
| 32.10 | A16AB03 | agalsidáza alfa | parent. | 1.00 | MG | 17 298,21 | Z |
| |
| 32.11 | A16AB04 | agalsidáza beta | parent. | 5.00 | MG | 17 298,21 | Z |
| |
| 32.12 | A16AB05 | laronidáza | parent. | 1.00 | DF | 32 508,91 | Z |
| 13206 | ALDURAZYME | inf cnc sol 1x5ml | GBZ | GB |
| 13207 | ALDURAZYME | inf cnc sol 10x5ml | GBZ | GB |
| 13208 | ALDURAZYME | inf cnc sol 25x5ml | GBZ | GB |
| 26354 | ALDURAZYME | inf cnc sol 1x5ml | GZE | NL |
| 32.13 | A16AX01 | kyselina tioktová | parent. | 0.20 | GM | 79,25 | O |
| 55381 | THIOGAMMA 600 INJECT | inj 500x20ml/600mg | SLH | D |
| 84380 | THIOGAMMA 600 INJECT | inj 50x20ml/600mg | SLH | D |
| 84381 | THIOGAMMA 600 INJECT | inj 100x20ml/600mg | SLH | D |
| 84382 | THIOGAMMA 600 INJECT | inj 1000x20ml/600mg | SLH | D |
| 32.14 | A16AX06 | miglustat | p.o. | 0.30 | GM | 9 513,04 | Z |
| |
| 33 | antithrombotika ze skupiny antagonistů vitaminu K |
| |
| 33.1 | B01AA03 | warfarin | p.o. | 7.50 | MG | 3,15 | |
| 58161 | LAWARIN 2 | tbl 50x2mg | PVL | CZ |
| 58162 | LAWARIN 5 | tbl 50x5mg | PVL | CZ |
| 94114 | WARFARIN ORION 5 MG | tbl 100x5mg | ORN | SF |
| 33.2 | B01AA08 | ethylbiskumacetát (do 75 mg v jedné tabletě včetně) | p.o. | 0.60 | GM | 3,52 | |
| |
| 33.3 | B01AA08 | ethylbiskumacetát (nad 75 mg v jedné tabletě) | p.o. | 0.60 | GM | 4,20 | |
| |
| 34 | antithrombotika ze skupiny heparinu a antithrombinu III |
| |
| 34.1 | B01AB01 | heparin | parent. | 10.00 | KU | 13,02 | O |
| |
| 34.2 | B01AB02 | antithrombin | parent. | 2.10 | KU | 23 699,53 | U |
| 93174 | ANTITHROMBIN III IMMUNO | inj pso Iqf 1x1ku | BXG | A |
| 35 | antithrombotika ze skupiny nízkomolekulárních heparinů |
|
| 35.1 | B01AB | certoparin | parent. | 3.00 | KU | 75,05 | P |
| 31316 | TROPARIN AMPOULE | inj 10x0.5ml/32mg | BCA | A |
| 35.2 | B01AB04 | dalteparin do 2,5 KU včetně v jedné ampuli | parent. | 3.00 | KU | 62,99 | P |
| |
| 35.3 | B01AB04 | dalteparin nad 2,5 KU do 5 KU včetně v jedné ampuli | parent. | 3.00 | KU | 62,94 | P |
| |
| 35.4 | B01AB04 | dalteparin nad 5 KU v jedné ampuli | parent. | 3.00 | KU | 48,47 | P |
| |
| 35.5 | B01AB05 | enoxaparin do 20 mg včetně v jedné ampuli | parent. | 3.00 | KU | 62,99 | P |
| |
| 35.6 | B01AB05 | enoxaparin nad 20 mg do 40 mg včetně v jedné ampuli | parent. | 3.00 | KU | 62,94 | P |
| |
| 35.7 | B01AB05 | enoxaparin nad 40 mg do 80 mg včetně v jedné ampuli | parent. | 3.00 | KU | 58,38 | P |
| |
| 35.8 | B01AB05 | enoxaparin nad 80 mg do 100 mg v jedné ampuli včetně | parent. | 3.00 | KU | 48,47 | P |
| |
| 35.9 | B01AB05 | enoxaparin nad 100 mg v jedné ampuli | parent. | 3.00 | KU | 38,70 | P |
| |
| 35.10 | B01AB06 | nadroparin do 2,85 KU včetně v jedné ampuli | parent. | 3.00 | KU | 62,99 | P |
| |
| 35.11 | B01AB06 | nadroparin nad 2,85 do 3,8 KU včetně v jedné ampuli | parent. | 3.00 | KU | 62,94 | P |
| |
| 35.12 | B01AB06 | nadroparin nad 3,8 do 7,6 KU včetně v jedné ampuli | parent. | 3.00 | KU | 58,38 | P |
| |
| 35.13 | B01AB06 | nadroparin nad 7,6 KU do 10 KU v jedné ampuli včetně | parent. | 3.00 | KU | 48,47 | P |
| |
| 35.14 | B01AB06 | nadroparin nad 10 KU v jedné ampuli | parent. | 3.00 | KU | 38,70 | P |
| |
| 35.15 | B01AB07 | parnaparin do 3,2 KU v jedné ampuli včetně | parent. | 3.00 | KU | 62,99 | P |
| |
| 35.16 | B01AB07 | parnaparin nad 3,2 do 4,250 KU včetně v jedné ampuli | parent. | 3.00 | KU | 62,94 | P |
| |
| 35.17 | B01AB07 | parnaparin nad 4,250 KU v jedné ampuli | parent. | 3.00 | KU | 58,38 | P |
| |
| 35.18 | B01AB08 | reviparin do 1,432 KU včetně v jedné ampuli | parent. | 3.00 | KU | 62,99 | P |
| |
| 35.19 | B01AB08 | reviparin nad 1,432 KU v jedné ampuli | parent. | 3.00 | KU | 62,94 | P |
Low molecular heparin for outpatient care can only be prescribed for the recipe:
1) in indication of treatment with deep vein thromboses confirmed by the dopler assay (dalteparin, enoxaparin, nadroparin, reviparin, parpurin)
2) Preventing blood clotting in extracurricular circulation, e. g. in haemodialysis and haemophilia (dalteparin, enoxaparin, nadroparin, reviparin)
3) in the prophylaxis of thromboembolism in the perioperative period, i. e. if outpatient switching from oral anticoagulants to low molecular heparin (dalteparin, enoxaparin, nadroparin, parpurin, reviparin) for maximal duration. 5 days
4) for the treatment of conditions requiring anticoagulant treatment during pregnancy or prior to cardiac transplantation (dalteparin, enoxaparin, nadroparin)
5) prevention and treatment of deep vein thrombosis in patients with evidence of congenital or acquired hypercoagulation conditions in whom the required reduction in coagulation factors by oral anticoagulants cannot be stabilised or if the anticoagulants cannot be administered (dalteparin, enoxaparin, nadroparin)
| 35.20 | B01AB11 | sulodexid | parent. | 600.00 | U | 62,00 | O |
| |
| 35.21 | B01AB11 | sulodexid | p.o. | 250.00 | U | 10,36 | L/OPH,INT,NEU, DIA,GER |
| |
| 36 | antiagregancia kromě heparinu |
| |
| 36.1 | B01AC | lysin acetylosalicylát (do 160 mg ekvivalentu kys. acetylosalicylové včetně v jedné dávce) | p.o. | 1.00 | DF | 0,66 | |
| |
| 36.2 | B01AC | lysin acetylosalicylát (nad 160 mg ekvivalentu kys. acetylosalicylové v jedné dávce) | p.o. | 1.00 | DF | 0,63 | |
| |
| 36.3 | B01AC04 | klopidogrel | p.o. | 75.00 | MG | 47,89 | P |
Internist or cardiologist prescribes treatment with clopidogrel:
(a) preventing recurrence of coronary events in patients with acute coronary syndrome without ST elevation (unstable angina or myocardial infarction without ST elevation) for 6 months,
(b) after intravascular interventions with a high risk of thrombosis (stent implantation, rotabulation, atherectomy, direct coronary angioplasty), usually in combination with K. acetylsalicylic for one month or for the so-called "film" stents releasing sirolimus or paclitaxel for 3 months.
Comments 0